Literature DB >> 7605915

Cholinesterase inhibitors increase secretion of APPs in rat brain cortex.

F Mori1, C C Lai, F Fusi, E Giacobini.   

Abstract

We examined whether cholinesterase inhibitors (ChEI) could alter the release of amyloid precursor protein (APP) from superfused brain cortical slices of the rat. Three ChEI, both reversible and irreversible, were tested for their ability to enhance the release of nonamyloidogenic soluble derivatives (APPs). These included: physostigmine (PHY), heptyl-physostigmine (HEP) and 2,2-dichloro-vinyldimethyl phosphate (DDVP), at concentrations producing cholinesterase (ChE) inhibition ranging from 5% to 95%. All three ChEI elevated APPs release significantly above control levels. Electrical field stimulation significantly increased the release of APPs within 50 min. Similar increase was observed after muscarinic receptor stimulation with bethanechol (BETHA). Tetrodotoxin (TTX) completely blocked the effect of electrical stimulation. These findings suggest that administration of ChEI to Alzheimer's disease (AD) patients may have a neuroprotective effect by activating normal APP processing.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7605915     DOI: 10.1097/00001756-199503000-00012

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  27 in total

1.  Neuroprotection in Alzheimer's disease - new strategies for treatment.

Authors:  A Nordberg
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

Review 2.  The cholinergic system in the pathophysiology and treatment of Alzheimer's disease.

Authors:  Harald Hampel; M-Marsel Mesulam; A Claudio Cuello; Martin R Farlow; Ezio Giacobini; George T Grossberg; Ara S Khachaturian; Andrea Vergallo; Enrica Cavedo; Peter J Snyder; Zaven S Khachaturian
Journal:  Brain       Date:  2018-07-01       Impact factor: 13.501

3.  Memory-enhancing effects of secreted forms of the beta-amyloid precursor protein in normal and amnestic mice.

Authors:  H Meziane; J C Dodart; C Mathis; S Little; J Clemens; S M Paul; A Ungerer
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-13       Impact factor: 11.205

Review 4.  Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology.

Authors:  A Nordberg; A L Svensson
Journal:  Drug Saf       Date:  1998-12       Impact factor: 5.606

5.  Neuronal-glial interactions mediated by interleukin-1 enhance neuronal acetylcholinesterase activity and mRNA expression.

Authors:  Y Li; L Liu; J Kang; J G Sheng; S W Barger; R E Mrak; W S Griffin
Journal:  J Neurosci       Date:  2000-01-01       Impact factor: 6.167

Review 6.  Cholinesterases: new roles in brain function and in Alzheimer's disease.

Authors:  Ezio Giacobini
Journal:  Neurochem Res       Date:  2003-04       Impact factor: 3.996

Review 7.  Basal forebrain cholinergic dysfunction in Alzheimer's disease--interrelationship with beta-amyloid, inflammation and neurotrophin signaling.

Authors:  Reinhard Schliebs
Journal:  Neurochem Res       Date:  2005 Jun-Jul       Impact factor: 3.996

8.  Presenilin 1 interacts with acetylcholinesterase and alters its enzymatic activity and glycosylation.

Authors:  María-Ximena Silveyra; Geneviève Evin; María-Fernanda Montenegro; Cecilio J Vidal; Salvador Martínez; Janetta G Culvenor; Javier Sáez-Valero
Journal:  Mol Cell Biol       Date:  2008-02-25       Impact factor: 4.272

Review 9.  Cholinergic treatments with emphasis on m1 muscarinic agonists as potential disease-modifying agents for Alzheimer's disease.

Authors:  Abraham Fisher
Journal:  Neurotherapeutics       Date:  2008-07       Impact factor: 7.620

10.  Synthesis, pharmacological assessment, and molecular modeling of acetylcholinesterase/butyrylcholinesterase inhibitors: effect against amyloid-β-induced neurotoxicity.

Authors:  Daniel Silva; Mourad Chioua; Abdelouahid Samadi; Paula Agostinho; Pedro Garção; Rocío Lajarín-Cuesta; Cristobal de Los Ríos; Isabel Iriepa; Ignacio Moraleda; Laura Gonzalez-Lafuente; Eduarda Mendes; Concepción Pérez; María Isabel Rodríguez-Franco; José Marco-Contelles; M Carmo Carreiras
Journal:  ACS Chem Neurosci       Date:  2013-02-04       Impact factor: 4.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.